HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Halozyme Therapeutics (HALO) Tops Q1 EPS by 10c, Beats on Revenue; Offers Guidance

May 7, 2024 4:05 PM EDT

Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.79, $0.10 better than the analyst estimate of $0.69. Revenue for the quarter came in at $196 million versus the consensus estimate of $199.74 million.

GUIDANCE:

Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90. Halozyme Therapeutics sees FY2024... More